The stock of Johnson & Johnson JNJ -0.19% rose slightly premarket on Tuesday after the healthcare giant provided guidance for 2024 as well as for the long term. This was ahead of a New York Stock Exchange investor day. The company expects sales to increase 5%-6% in 2024 and adjusted earnings to range between $10.55 and $10.75. This includes the recently announced acquisition by Laminar Inc., which will reduce earnings by 15 cents. FactSet’s consensus for EPS is $10.78. The company anticipates that its enterprise division will grow by at least 3% in operational sales in 2025, despite the fact that Stelara, which is a treatment to treat plaque psoriasis or psoriatic arthritics, may face competition from a biosimilar in the U.S. From 2025 to 2030, it expects to see a compound annual growth of 5% to 7.5% in its operational sales. It expects that the operational sales of the medtech sector will be in the upper end of the market, with a growth rate between 5% and 7% expected through 2027. From 2025 to 2030, innovative medicine will see an increase in operational sales of 5% to 7 %. The stock is down 10% year-to-date, while S&P500 SPX is up 19%.